Objective-A high thrombin generation level has been associated with the risk of venous thrombosis. Whether changes in this biomarker are relevant to arterial disease remains unknown. We investigated the association of thrombin generation with coronary heart disease (CHD) and acute ischemic stroke (AIS) in the elderly. Methods and Results-We used data from the Three-City study, a prospective cohort including 9294 subjects aged Ͼ65 years. After 4 years of follow-up, a case-cohort study was established. Using the calibrated automated thrombography method, endogenous thrombin potential and peak height were measured in plasma samples of all CHD and AIS cases and a random sample of 1177 controls. We did not find any significant association between thrombin generation and CHD. In multivariate analyses, high levels of endogenous thrombin potential and peak height were associated with an increased risk of AIS (hazard ratioϭ1.16 [95% CI, 0.90 to 1.50] and 1.31 [95% CI, 1.01 to 1.69] for a 1 SD increase, respectively). Data also suggested that these associations might be more important in women (hazard ratioϭ1.55 [95% CI, 1.05 to 2.33] and 1.71 [95% CI, 1.11 to 2.63], respectively) than in men (P for interactionϭ0.04 and 0.08, respectively).
T hrombin is the key product of the coagulation system and is produced following activation of factor X by tissue factor/factor VIIa. This in turn activates platelets and other coagulation factors, leading to clot formation. 1 Recently, an efficient method to measure thrombin generation in vitro has been developed. 2 This assay is an automated method (calibrated automated thrombography) in which tissue factor, phospholipids, and CaCI 2 are used to trigger the coagulation.
Using the calibrated automated thrombography method may provide an efficient tool to detect hypercoagulatibility, and several studies have reported a relationship between thrombin generation and the incidence of venous thrombosis [3] [4] [5] [6] and recurrent venous thrombosis. [7] [8] [9] There is also increasing evidence of an association between venous thrombosis and subsequent atherothrombosis, 10, 11 with both conditions sharing risk factors. Moreover, factors associated with thrombin generation have been associated with the risk of myocardial infarction (MI) and stroke. 12 However, to date no study has investigated whether thrombin generation may also be associated with the risk of coronary heart disease (CHD) and stroke. Establishing a relationship between thrombin generation and cardiovascular diseases would not only contribute to our current understanding of the physiopathological processes leading to coronary thrombosis and acute ischemic stroke (AIS) but also suggest a new approach to prevention.
Using data from a large prospective cohort study (the Three-City study), we have investigated the relationship between thrombin generation and incidence of CHD and AIS.
Methods

Study Population
This study is part of a large, ongoing French prospective study aimed at evaluating the risk of dementia attributable to vascular disorder. Detailed methodology has been previously described. 13 Briefly, between 1999 and 2001, 9294 men and women were recruited in 3 French cities (Bordeaux, Dijon, and Montpellier). Subjects had to be registered on electoral rolls, aged Ն65, and not institutionalized. The protocol of the Three-City study was approved by the Consultative Committee for Protection of Persons Participating in Biomedical Research of the University Hospital of Kremlin-Bicêtre (Paris), and all subjects signed a legal consent form.
Since their recruitment, subjects have been followed every 2 years for the detection of cardiovascular disease and dementia. For the present analysis, we used data up to the second follow-up (approximately 4 years after inclusion).
Event Ascertainment
At baseline, history of vascular disease and cardiovascular risk factors were assessed during the face-to-face interview. History of MI, angina pectoris, and stroke were identified, and subjects who reported a past history of stroke underwent further examination. For the study of CHD, subjects with previous angina pectoris or MI were excluded (nϭ115). Similarly, for the study of incident AIS, subjects with previous stroke were excluded (nϭ51).
An independent committee of trained physicians reviewed all possible cases of CHD. A CHD case was defined as a hospitalized stable or unstable angina pectoris, a coronary dilatation or artery bypass, a hospitalized MI, or a validated CHD death (coded I210 to I219, I251 to I259, I461, and R960 according to the International Classification of Diseases 10). After 4 years of follow-up, the total number of new CHD cases was 216. The 4-year cumulative incidence of CHD in the whole cohort was 0.79%.
Similarly, an independent panel of experts reviewed all possible cases of stroke. The definition of stroke is the rapid onset of a neurological deficit confirmed by a lesion compatible with an acute stroke on tomography or magnetic resonance imaging of the brain. AIS and hemorrhagic stroke were differentiated using brain imaging. In this analysis, we focused on the study of AIS. After 4 years of follow-up, the total number of new AIS cases was 94. The 4-year cumulative incidence of AIS in the whole cohort was 0.31%. In addition, subtypes of AIS were classified according to the Trial of Org10172 in Acute Stroke Treatment classification. 14 In this study, AIS was categorized as cardioembolic, atherothrombotic, lacunar (simple or multiple), iatrogenic, or undetermined. Ischemic fatal and nonfatal strokes were included in our analyses.
Case-Cohort Design
Recently, a case-cohort study 15 has been established within the Three-City study to investigate the effect of biological markers on the risks of cardiovascular disease or dementia. The methodology of this design has been described in detail elsewhere. 16 In brief, a case-cohort design involves a randomly selected sample from the initial cohort, as well as all incident cases of this cohort. In practice, we randomly selected 1254 subjects from the initial cohort, stratified by center, sex, and age and for whom blood sample had been collected. For the study of cardiovascular events, we added all incident cases of CHD and stroke occurring within the first 4 years of follow-up who had not already been selected in the random sample (nϭ166 and nϭ103, respectively). Similarly, all remaining incident cases of dementia were added to the study sample (nϭ218) but are not included in our present analysis.
Blood Collection and Hemostatic Factors Measurements
At baseline, blood samples were collected for 90% of the entire cohort. Subjects included in the case-cohort design had all agreed to venipuncture. Citrated plasma samples were obtained after 1 centrifugation (3000g at 4°C) and immediately stored at Ϫ80°C in 500-L plastic tubes. Fibrinogen was measured using the kinetic method of Clauss (Dade Behring, Paris, France), and von Willebrand factor and fibrin D-dimer by ELISAs from Stago (Asserachrom von Willebrand factor and D-Di, Asnieres sur Seine, France).
DNA was extracted centrally by the salt precipitation method, and purified genomic DNA was stored at Ϫ20°C. Factor V Leiden mutation and G20210A prothrombin mutation (rs1799963) were systematically genotyped for the overall cohort. Genotyping was centrally performed by KBioscience (Hoddesdon Herts, United Kingdom) using the KBioscience competitive Allele-Specific polymerase chain reaction single-nucleotide polymorphism genotyping system with fluorescence reasonance energy transfer quencher cassette oligos (KASPar). 17
Thrombin Generation Measurements
Thrombin generation was measured at baseline using the calibrated automated thrombography method as described by Hemker et al 2 at final concentration of 5 pmol/L tissue factor (Innovin, Siemens) and 4 mol/L phospholipids (MP reagent, Thrombinoscope). Thrombin calibrator and the fluorogenic substrate FluCa were from Thrombinoscope (Maastricht, the Netherlands). After exclusion of subjects taking anticoagulant therapy (nϭ48) and subjects for whom thrombin generation could not be assessed (nϭ29), thrombin generation parameters were successfully measured for 1177 subjects from the random sample, 157 additional cases of CHD, and 76 additional AIS cases ( Figure) . Excluded subjects did not differ from the retained sample in term of age, sex, body mass index (BMI), or other cardiovascular risk factors.
We studied 2 thrombogram parameters: peak height of thrombin generation and endogenous thrombin potential (ETP), which corresponds to the area under the thrombogram curve.
Statistical Analysis
Characteristics of subjects included in the random sample are given as meanϮSD for continuous variables and as frequency and percentages for categorical variables. Mean (SD) of ETP and peak height are given according to subject characteristics. Associations were tested using univariate linear regression models, with thrombin generation measures as the dependent variable. ETP and peak height generation were log-transformed to approximate normal distribution. Regarding cardiovascular risk factors at inclusion, tobacco use was studied in 2 categories (never smoker or ever smoker). Hypertension was defined as a systolic blood pressure Ն160 mm Hg, a diastolic blood pressure Ն95 mm Hg, or the subject taking an antihypertensive drug. Hypercholesterolemia was considered present if the level of cholesterol was Ն6.20 mmol/L. Diabetes included a diagnosis of diabetes, fasting blood glucose of 7 mmol/L, or a treatment for diabetes. BMI was studied as a continuous variable or dichotomized as BMI Ͻ27.5 kg/m 2 or Ն27.5 kg/m 2 , which has been recommended as a cut-off for preobesity/obesity by the World Health Organization. 18 In addition, Pearson correlations were measured between hemostatic parameters and thrombin generation. Risks of CHD and AIS associated with ETP and peak height was assessed using weighted Cox proportional hazards regressions with modification of the standard errors based on robust variance estimates to take into account case-cohort design. 15 The risk of incident CHD was measured for all CHD cases, as well as by disease severity (MI/angina pectoris, coronary dilatation, or artery bypass). Age was used as the time scale in all analyses; thus, the hazard ratio (HR) was always adjusted for age. The model used also took into account late entry. 19 To assess the linearity of the relation between both thrombin generation parameters and the risk of CHD and AIS, we used tests based on the difference in the log likelihood between 2 models of prediction (one with 3 dummy variables corresponding to the quartiles of the parameter distribution and the other including the continuous variable). All tests were not significant, allowing us to not reject the hypothesis of linearity. HR are thus displayed for a 1 SD increase of ETP or peak height in crude and adjusted models. Adjustments were made for cardiovascular risk factors, including sex, tobacco use, diabetes, hypertension, hypercholesterolemia, and BMI. Finally, the differential effect of ETP and peak height according to gender was tested using both multiplicative and additive interaction scale. Regarding the assessment of additive interactions, we measured the relative excess risk due to interaction. 20,21 SAS statistical software version 9.1 was used for statistical analyses (SAS Institute Inc., Cary, NC). Table 1 displays ETP and peak height values according to subjects' characteristics. Overall, the mean of ETP was 1785 nmol/L per minute (SDϭ288), and the mean of peak height was 337 nmol/L (SDϭ50.3). We found positive and significant associations of BMI, hypercholesterolemia, and prothrombin G20210A mutation with ETP and peak height. The correlations between ETP and fibrinogen and D-dimer were rϭ0.21 (PϽ0.0001) and rϭ0.17 (Pϭ0.015), respectively. Similarly, correlations between peak height and fibrinogen and von Willebrand factor were rϭ0.19 (PϽ0.0001) and rϭ0.11 (PϽ0.001), respectively.
Results
Thrombin Generation and Subjects' Characteristics
Thrombin Generation and CHD
During the 4 years of follow-up, among subjects included in our analysis, 186 subjects had a CHD event (15.7%). Of these, MI was present in 88 subjects, and the others presented angina pectoris, coronary dilatation, or artery bypass. Overall, 36 events were fatal. We did not find a significant association between thrombin generation and the HR of total CHD, MI, or other CHD ( Table 2 ). After adjustment for traditional cardiovascular risk factors, the HR of CHD was 1.09 (95% CI, 0.92 to 1.28) for a 1 SD elevation in ETP and 1.02 (95% CI, 0.89 to 1.17) for a 1 SD elevation in peak height.
A sensitivity analysis consisting of the exclusion of prevalent cases of stroke (nϭ49) from our sample did not show different results. The HR values of CHD associated with a 1 SD increase in ETP and peak were 1.11 (95% CI, 0.93 to 1.33) and 1.03 (95% CI, 0.90 to 1.18), respectively.
Thrombin Generation and AIS
Overall, in our sample, 87 subjects had an AIS during the follow-up (7.5%) 3 of which were fatal. We found a borderline significant association of ETP and peak height with the HR of AIS (HRϭ1.16 [95% CI, 0.90 to 1.48] and HRϭ1.27 [95% CI, 1.00 to 1.62], respectively) ( Table 3 ). Further excluding prevalent CHD cases (nϭ121) from our sample did not product different results. The HR values of AIS associated with a 1 SD increase in ETP and peak were 1.21 (95% CI, 0.90 to 1.62) and 1.34 (95% CI, 1.02 to 1.76), respectively.
In addition, we found some evidence of an interaction between sex and thrombin generation on the risk of AIS. The adjusted HR of AIS associated with both ETP and peak height was significantly increased in women (HRϭ1.55 [95% CI, 1.03 to 2.33] and HRϭ1.71 [95% CI, 1.11 to 2.63], respectively) but not in men. Probability values for interaction measured on a multiplicative scale were 0.04 and 0.08 for ETP and peak height, respectively. We also found evidence of a departure from additivity for ETP and sex. The relative excess risk due to interaction of both sex and ETP was Ϫ1.7 (95% CI, Ϫ38.0 to 0.26, Pϭ0.09). Regarding peak height, the relative excess risk due to interaction was Ϫ1.8 (95% CI, Ϫ20.5 to 5.56, Pϭ0.33). These results indicate, for example, that because of the interaction between sex and ETP, the HR for AIS was 1.7 lower than expected from the addition of the separate effects of sex and ETP. Being male seemed to protect subjects with increased level of ETP from the occurrence of AIS. Stratified analyses showed that the HR of AIS was consistently associated with an increased thrombin generation in all subgroups of women at higher or lower risk for cardiovascular disease (data not shown). Finally, when we studied the subtype of ischemic stroke, the risks associated with ETP and peak height were particularly elevated for cardioembolic stroke (adjusted HRϭ2.05 [95% CI, 0.87 to 4.80] and 2.86 [95% CI, 1.08 to 7.52], respectively), although they were not significant for other subtypes.
Discussion
In the present analyses, we evaluated the risk of arterial disease associated with thrombin generation. We found that elevated thrombin generation was an independent risk factor for AIS but not for CHD. This result appeared more relevant among women, although the interaction was borderline significant.
Several methods have been proposed to measure thrombin generation, and differences in assays may at least partially explain discrepancies in previous studies. We did, however, observe a number of expected associations between thrombin generation and biological variables. Indeed, we noted a strong relationship between prothrombin G20210A mutation and higher level of thrombin generation. This result is consistent with other studies 4, 6, 8, 22 and has strong biological support. In reality, prothrombin G20210A mutation is associated with higher levels of plasma prothrombin, which is a direct determinant of thrombin generation. We also found that thrombin generation was positively correlated with fibrino- 55 (1.03 to 2.33)  1.71 (1.11 to 2.63) P for multiplicative interaction between ETP/peak height and sex on the risk of AIS was 0.04/0.08. Relative risk due to interaction of ETP/peak height and sex was Ϫ1.7/Ϫ1.8, Pϭ0.09/0.33. Significant associations are given in boldface. GM indicates geometric mean; IQR, interquartile range.
*Adjusted for classical cardiovascular risk factors: center, sex (when appropriate), BMI Ն27.5 kg/m 2 , hypertension, hypercholesterolemia, diabetes, tobacco use (never or ever smoker).
gen, which is a positive determinant of thrombin formation. 23 Regarding D-dimer, it is interesting to note that the correlation with ETP was slightly lower than between fibrinogen and ETP. This result is in accordance with recent findings suggesting that ETP and D-dimer may reflect different aspects of the coagulation system. 7, 8 ETP represents the amount of thrombin that could potentially be generated, whereas D-dimer is a marker of ongoing coagulation in vivo.
Most importantly, we found a significant association between thrombin generation and AIS. This result has never been reported before and suggests an important role of hypercoagulability in the pathogenesis of AIS. This result is in accordance with some previous studies, which showed a positive association between hemostatic variables and the risk of subsequent stroke. 24, 25 However, we failed to find a significant association between thrombin generation and the risk of CHD. First, we cannot exclude a lack of statistical power to detect a true but small association between thrombin generation and the risk of CHD. Second, our result is in accordance with evidence of discrepancy in risk factors between AIS and CHD. For example, oral use of hormone therapy among postmenopausal women, strongly associated with a rise in coagulation factors, results in an increased risk of stroke 26 -28 whereas a protective effect of these treatments has been suggested regarding the risk of CHD. 29 Finally, a recent study of arterial disease among women 30 reported that the effect of lupus anticoagulants, a type of antiphospholipid antibodies known to induce a prothrombotic state, was more pronounced on the risk of AIS than on the risk of MI. Together with our data, these results are in favor of a stronger implication of a hypercoagulable state on the risk of AIS than on the risk of CHD.
We found a possible differential association of thrombin generation with the risk of AIS according to sex. Many studies have emphasized sex-specific risk profiles of stroke, acute stroke presentation, and stroke etiology. 31 For example, hormone therapy could explain this difference. As we mentioned above, hormone therapy increases the risk of stroke. 26 -28 Moreover, oral estrogen use in postmenopausal women has been associated with higher risk of venous thromboembolism through increased coagulation and inflammation. 32 In our study, we observed an increased level of thrombin generation in women using oral estrogen versus nonusers. However, because of the small number of women using oral estrogen, we were unable to reliably evaluate the impact of estrogen use on the association between thrombin generation and AIS. This issue remains to be addressed in future studies. Another important determinant of the sexspecific risk of stroke is atrial fibrillation (AF). Although it is more prevalent in men than women, 33 growing evidence supports the idea that AF is a greater risk factor for stroke in women than men. 34 -36 Our data are consistent with this result, as we found an elevated risk of AIS associated with AF, and this risk was more pronounced in women than in men (data not shown). Combined with AF, a high potential of thrombin generation may increase the risk of AIS. In this manner, thrombin generation would be a marker of thromboembolism rather than atherothrombosis. We could not test this hypothesis because there were too many missing value for the status of AF. However, the fact that we found a positive association between thrombin generation and cardioembolic stroke but not with other subtypes in women gives additional support to this hypothesis. Of note, if thrombin generation is a marker of thromboembolism rather than atherothrombosis, it could also explain why we did not find any association between thrombin generation and CHD.
Our study presents some strengths and some limitations. First, the prospective nature of the design and the high participation rate during the 4 years of follow-up (92%) are 2 major strengths. In addition, incident events were carefully validated by an independent committee of experts. Regarding the methodology used to assess thrombin generation, we chose a concentration of tissue factor that was not sensitive to contact factor activation but relatively highly efficient to detect hypercoaguability. [37] [38] [39] [40] The main limitation of our study is the small number of incident cases, which may result in a lack of statistical power. In our study, the low incidence of events may have been due to the restriction of our study to community-dwelling residents with better physical and cognitive abilities than the general elderly population. 13 As a consequence, we may have underestimated the association of thrombin generation with the risk of CHD. Therefore, investigating the association of thrombin generation with the risk of arterial disease is needed in other studies. Finally, given our study sample, the association found between thrombin generation and AIS pertains only to subjects older than 65.
As growing evidence supports an association between elevated thrombin generation and risk of venous thrombosis, our results regarding AIS, particularly in women, constitutes a new and interesting finding requiring validation in other populations. If our results are confirmed, prevention of AIS should target the diminution of the thromboembolic risk together with prevention of atherosclerosis.
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